Pozniak A - Search Results

1

Large disparities in HIV treatment cascades between eight European and high-income countries - analysis of break points.

Raymond A, Hill A, Pozniak A. Raymond A, et al. Among authors: pozniak a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19507. doi: 10.7448/IAS.17.4.19507. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394016 Free PMC article.

2

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG, Pozniak AL. Boffito M, et al. Among authors: pozniak al. AIDS. 2004 Jun 18;18(9):1291-7. doi: 10.1097/00002030-200406180-00007. AIDS. 2004. PMID: 15362661

3

Causes and consequences of incomplete HIV RNA suppression in clinical trials.

Pozniak A, Gupta RK, Pillay D, Arribas J, Hill A. Pozniak A, et al. HIV Clin Trials. 2009 Sep-Oct;10(5):289-98. doi: 10.1310/hct1005-289. HIV Clin Trials. 2009. PMID: 19906623 Review.

4

A normal life expectancy, despite HIV infection?

Hill A, Pozniak A. Hill A, et al. Among authors: pozniak a. AIDS. 2010 Jun 19;24(10):1583-4. doi: 10.1097/QAD.0b013e32833ac7d4. AIDS. 2010. PMID: 20479635 No abstract available.

5

Does pregnancy affect the pharmacokinetics of efavirenz?

Hill A, Ford N, Boffito M, Pozniak A, Cressey TR. Hill A, et al. Among authors: pozniak a. AIDS. 2014 Jun 19;28(10):1542-3. doi: 10.1097/QAD.0000000000000279. AIDS. 2014. PMID: 24896806 No abstract available.

6

Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014-2018.

Hill A, Hill T, Jose S, Pozniak A. Hill A, et al. Among authors: pozniak a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19497. doi: 10.7448/IAS.17.4.19497. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394006 Free PMC article.

7

Acceptance rate of clinical study endpoints and adequacy of source documentation: experience from clinical study endpoint review in NEAT001/ANRS143.

Berenguer J, Wit F, Jansson PO, Schwimmer C, Kowalska JD, Saillard J, Diallo A, Pozniak AL, Raffi F, Grarup J. Berenguer J, et al. Among authors: pozniak al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19572. doi: 10.7448/IAS.17.4.19572. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394079 Free PMC article.

8

Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?

Hill A, Khoo S, Back D, Pozniak A, Boffito M. Hill A, et al. Among authors: pozniak a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19583. doi: 10.7448/IAS.17.4.19583. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394089 Free PMC article.

9

Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure.

Schultze A, Paredes R, Sabin C, Phillips AN, Pillay D, Kirk O, Lundgren JD, Pozniak A, Nelson M, Cozzi-Lepri A; Eurosida in Eurocoord. Schultze A, et al. Among authors: pozniak a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19737. doi: 10.7448/IAS.17.4.19737. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397482 Free PMC article.

10

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK.

El Bouzidi K, White E, Mbisa JL, Phillips A, Mackie N, Pozniak A, Dunn D. El Bouzidi K, et al. Among authors: pozniak a. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19739. doi: 10.7448/IAS.17.4.19739. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397484 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

558 results

Search Page

Filters